Accessibility Statement Skip Navigation
  • Back to Global Sites
  • +972-77-2005042
  • Blog
  • Journalists
  • GDPR
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +972-77-2005042 from 8 AM - 11 PM IL

    • Contact
    • Contact

      +972-77-2005042
      from 8 AM - 11 PM IL

  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR

Isotopia Announces the UK Launch of Isoprotrace®, an Innovative Diagnostic Solution for Prostate Cancer Imaging
  • USA - Français
  • USA - Deutsch
  • USA - English
  • USA - español
  • Italia - Italiano

Isotopia Logo

News provided by

Isotopia

10 Apr, 2025, 12:00 IDT

Share this article

Share toX

Share this article

Share toX

PETAH TIKVA, Israel, April 10, 2025 /PRNewswire/ -- Isotopia Molecular Imaging is proud to announce the official launch of Isoprotrace®, its advanced Gallium-68 Gozetotide preparation kit for prostate cancer imaging, in the United Kingdom.

This milestone underscores Isotopia's profound commitment to expanding access to high-quality diagnostic tools and improving patient care globally.

Isoprotrace® is an innovative PSMA-11 (Gozetotide) radiolabelling kit designed to enhance the precision of prostate cancer imaging. The ready-to-use, multi-dose kit facilitates the efficient preparation of Gallium-68 Gozetotide solution for intravenous injection, equipping healthcare providers with a critical tool for diagnosing prostate cancer and optimizing treatment plans.

Through a strategic partnership with Light Medical, Isotopia guarantees that Isoprotrace® will be readily available to medical facilities across the UK, thereby empowering clinicians to effectively detect and manage prostate cancer.

"The launch of Isoprotrace® in the United Kingdom represents a significant milestone in our mission to expand patient access to cutting-edge diagnostic solutions," said Tzachi Levy, General Manager of Isotopia's aseptic plant. "With the increasing demand for precision imaging in prostate cancer care," continued Mr. Levy, "Isoprotrace® offers healthcare professionals an essential tool to improve diagnostic accuracy and enhance treatment outcomes."

Mark Goodwin, Director at Light Medical, added, "We are honored to collaborate with Isotopia in introducing Isoprotrace® to the UK market. This launch marks a vital step forward in combating prostate cancer, and we are committed to ensuring widespread availability of this innovative diagnostic kit for healthcare providers nationwide."

Isotopia remains dedicated to maintaining a robust supply chain, thus ensuring seamless access to this essential diagnostic tool for healthcare providers and patients worldwide.

For more information about Isoprotrace®, including product specifications and availability, please visit https://isotopia-global.com/isoprotrace/

About Isotopia Molecular Imaging

Isotopia Molecular Imaging is a global leader in radiopharmaceutical development, specializing in theranostic solutions that enhance diagnostic accuracy and treatment efficacy. With a steadfast commitment to innovation and patient-centred  care, Isotopia delivers reliable, high-quality radiopharmaceuticals to healthcare providers worldwide.

https://isotopia-global.com/isoprotrace/

About Light Medical

Light Medical is a trusted distributor of advanced medical imaging solutions, dedicated to supporting healthcare professionals in delivering superior diagnostic and treatment options. By partnering with leading innovators like Isotopia, Light Medical ensures access to cutting-edge technologies that significantly improve patient outcomes.

https://www.lightmedical.co.uk/contact

Contact:
[email protected] 

Logo: https://mma.prnewswire.com/media/2659964/Isotopia_Logo.jpg

SOURCE Isotopia

Modal title

Also from this source

ASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies

ASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies

ASP Isotopes Inc. (NASDAQ: ASPI) and Isotopia Molecular Imaging Ltd. have entered into a strategic agreement to secure the supply of Gadolinium-160...

ASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies

ASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies

ASP Isotopes Inc. (NASDAQ: ASPI) and Isotopia Molecular Imaging Ltd. have entered into a strategic agreement to secure the supply of Gadolinium-160...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Medical Equipment

Medical Equipment

Computer & Electronics

Computer & Electronics

News Releases in Similar Topics

Contact PR Newswire

  • +972-77-2005042
    from 8 AM - 11 PM IL

Global Sites

  • APAC
  • APAC - Traditional Chinese
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany

 

  • India
  • Indonesia
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland

 

  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921
Global Sites
  • Asia
  • Brazil
  • Canada
  • Csezh
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italie
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
+972-77-2005042
from 8 AM - 11 PM IL
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2025 Cision US Inc.